Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 580

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 6
Chunk 580
---
 Research”). Aon has no other connection with the Company or individual Directors. The Remuneration Committee comprehensively reviewed the Group’s compensation and share-based incentives policies, the Aon Benchmarking Research and established an attractive policy to ensure the Group is able to recruit and retain top talent. Vesting of share-based awards under such policy is in line with the referenced peer group. The Committee takes seriously its responsibility to ensure that the executive remuneration practices of the Group drive strong performance, are aligned with the strategy and sustainability of the Group and are appropriate in the context of the external regulatory environment and the expectations of stakeholders.
​

Shareholder return comparison 
The independent remuneration advisor, Aon also reviewed the total shareholder return comparator group used as a component of the company’s performance based LTIP awards for 2024, using volatility and correlation analysis to evaluate the appropriateness of this peer group. It encouraged the Company to use peer groups of approximately 30 companies or more. It focused on three primary and four secondary criteria. Primary criteria for peers selection were their industry sector, centering on, commercial companies with innovative specialty biopharmaceutical medicines or drug candidates; their listing location, centering on China or the United States; and those with a three-year stock price that correlated with the Company. Secondary criteria were their therapeutic focus, prioritizing companies with marketed products and development pipelines focused on oncology therapies; their stock price volatility; their market capitalization, excluding micro-cap and large-cap companies; and their share trading history, excluding companies that have not been public for at least three years.
Executive Officer Compensation
Summary Compensation Table
The following table sets forth the non-equity compensation paid or accrued during the year ended December 31, 2024 to our chief executive officer and chief scientific officer, chief financial officer and other executive officers on an aggregate basis. 

                    ​                       ​       ​        ​         ​       ​      ​       ​        ​        ​         ​         ​       ​    
-------------------------------------------------------------------------------------------------------------------------------------------------
​                                               Salary             ​               Taxable        Non-taxable       Pension             ​        
​                                           ​   and fees    ​      Bonus       ​   benefits   ​   benefits      ​   contributions   ​   Total    
Name and Principal Position                 ​   ($)         ​      ($)         ​   ($)        ​   ($)           ​   ($)             ​   ($)      
Weiguo SU                                       886,677     (1)​   1,282,051       —          ​   8,656